Skip to content
Brilliant Blue Biosciences logoBrilliant BlueBiosciences
Articles

Papers, explained in our own words

Every entry summarises what the study set out to test, what it found and why it changes how we design delivery systems. Browse research and reviews or search the collection.

706 articles

Showing 25–39 of 39 articles · Keyword: PLGA Clear keyword

Frontiers in Pharmacology2018ReviewDrug Delivery

25. PLGA-Based Nanoparticles in Cancer Treatment

Sima Rezvantalab, Natascha Ingrid Drude, Mostafa Keshavarz Moraveji, Nihan Güvener, Emily Kate Koons, Yang Shi, Twan Lammers, Fabian Kiessling

PLGA-based nanoparticles are widely investigated for cancer therapy, but their clinical translation remains limited. A consolidated overview was needed of how PLGA NP physicochemical properties, biological behaviour, targeting strategies, and combination therapies interact—and why promising preclinical results have…

Read the article
Theranostics2017ReviewNon-viral Gene Delivery

26. Bioengineering of Artificial Antigen Presenting Cells and Lymphoid Organs

Chao Wang, Wujin Sun, Yanqi Ye, Hunter N. Bomba, Zhen Gu

Immune cell/organ therapies based on manipulation, infusion, and implantation of autologous or allogeneic cells/organs are costly, time-consuming, and sometimes limited in clinical effectiveness. Biomimetic materials and strategies offer an alternative by enabling artificial immune cells and lymphoid organs that are…

Read the article
Materials2017ReviewNon-viral Gene Delivery

27. Poly(Lactic-co-Glycolic Acid) Applications and Future Prospects for Periodontal Tissue Regeneration

Sun, X.; Wu, G.; Xu, C.; Ye, Q.; Wang, C

Periodontitis causes irreversible destruction of periodontal tissues, and regeneration requires biomaterials with suitable mechanical, degradation, and biological properties. PLGA is attractive for periodontal regeneration because of its biocompatibility, tunable degradation, and processability, but its…

Read the article
Advanced Drug Delivery Reviews2016ReviewNon-viral Gene Delivery

28. Gene Delivery Nanoparticles to Modulate Angiogenesis

Jayoung Kim, Adam C. Mirando, Aleksander S. Popel, Jordan J. Green

Angiogenesis is normally balanced by pro- and anti-angiogenic factors, but imbalance leads to aberrant angiogenesis in ischaemia, tissue regeneration, cancer, and neovascular age-related macular degeneration (wet AMD). Gene therapy is a promising strategy to introduce exogenous nucleic acids that express or silence…

Read the article
Advanced Drug Delivery Reviews2016ReviewNon-viral Gene Delivery

29. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery

Suk, J. S.; Xu, Q.; Kim, N.; Hanes, J.; Ensign, L. M

PEGylation is widely used to improve nanoparticle drug and gene delivery by reducing aggregation, opsonisation, and phagocytic clearance, thereby prolonging circulation. However, the field lacks a consolidated understanding of how PEG molecular weight, surface density, conformation, core properties, administration…

Read the article
Advanced Drug Delivery Reviews2015ReviewNon-viral Gene Delivery

30. In Vivo Delivery of miRNAs for Cancer Therapy: Challenges and Strategies

Yunching Chen, Dong-Yu Gao, Leaf Huang

miRNAs can simultaneously regulate multiple cancer-related genes, making them attractive therapeutic agents or targets. However, efficient, specific, and safe systemic delivery of therapeutic miRNAs in vivo remains a major challenge due to rapid degradation, poor tumour penetration, immunotoxicity, endosomal…

Read the article
Journal of Controlled Release2015ReviewDrug Delivery

31. Amphiphilic poly(amino acid) based micelles applied to drug delivery The in vitro and in vivo challenges and the corresponding potential strategies

Helin Xu, Qing Yao, Cuifang Cai, Jinxin Gou, Yu Zhang, Haijun Zhong, Xing Tang

Amphiphilic poly(amino acid)-based micelles are attractive for systemic drug delivery because they are biodegradable, biocompatible, have functional side groups, can load diverse drugs, and can exploit the EPR effect. However, low cargo capacity and poor stability in blood remain major barriers to clinical…

Read the article
2014ReviewNon-viral Gene Delivery

32. Nanocarrier-based immunotherapy in cancer management and research

Singh Ms, Bhaskar S.

Cancer immunotherapy can induce specific antitumor immunity, control metastases, and provide immunological memory, but faces barriers including immunosuppressive tumour microenvironments and poor delivery of immunomodulators. Nanocarriers offer a versatile way to deliver antigens, adjuvants, cytokines, antibodies…

Read the article
Journal of Controlled Release2012ReviewDrug Delivery

33. PLGA-based nanoparticles: An overview of biomedical applications

Fabienne Danhier, Eduardo Ansorena, Joana M. Silva, Regis Coco, Aude Le Breton, Véronique Préat

PLGA is one of the most successfully developed biodegradable polymers, with FDA and EMA approval for parenteral drug delivery, but a comprehensive overview linking its formulation methods, physicochemical pitfalls, targeting strategies, and applications across multiple diseases was needed. This review presents why…

Read the article
2011ReviewNon-viral Gene Delivery

34. Strategies for the intracellular delivery of nanoparticles

Chou Lyt, Ming K, Chan Wcw.

Nanoparticles (NPs) are increasingly used as contrast agents, therapeutics, and delivery vehicles, but their effective delivery into cells and to specific subcellular organelles remains a major challenge. The review addresses fundamental barriers to intracellular NP delivery—plasma membrane, endosomal entrapment…

Read the article
Polymers2011ReviewDrug Delivery

35. Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier

Hirenkumar K. Makadia And Steven J. Siegel

PLGA has become one of the most attractive biodegradable polymers for drug delivery and tissue engineering, but its degradation and drug-release behaviour depend on many interconnected variables—polymer composition, molecular weight, crystallinity, device geometry, fabrication method, and drug type. A consolidated…

Read the article
Expert Opinion on Drug Delivery2010ReviewNon-viral Gene Delivery

36. Lipid and polymeric carrier-mediated nucleic acid delivery

Zhu L, Mahato Ri

Nucleic acid therapeutics—plasmid DNA, antisense oligonucleotides, and RNAi molecules—have broad therapeutic potential but face major biological barriers, including nuclease degradation, poor membrane penetration, endosomal entrapment, nonspecific biodistribution, and immune activation. The review addresses how…

Read the article
Journal of drug targeting2008ReviewDrug Delivery

37. Polymeric nanoparticles for cancer therapy

Parveen, S.; Sahoo, S. K

Conventional cancer chemotherapy suffers from poor tumour selectivity, high required doses, systemic toxicity, rapid drug elimination, and multidrug resistance. Polymeric nanoparticles (NPs) are reviewed as a strategy to improve targeted delivery, controlled release, and therapeutic efficacy while reducing adverse…

Read the article
Nature Materials2006ReviewNon-viral Gene Delivery

38. Polymers for gene delivery across length scales

Putnam D

Synthetic polymer-based gene delivery vectors have been studied for two decades but remain far less efficient than viral vectors. The review addresses the need for improved design criteria and new synthetic strategies across nano-, micro-, and macroscale delivery systems to overcome formulation, organism-level, and…

Read the article
Advanced Drug Delivery Reviews2005ReviewNon-viral Gene Delivery

39. PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines

Ying Waeckerle-Men And Marcus Groettrup

Dendritic cell (DC)-based vaccines are limited by the short persistence of MHC class I/peptide complexes on the DC surface—often only a few hours—when soluble peptides are loaded exogenously. This short presentation limits CTL activation and vaccine efficacy. The authors investigated biodegradable PLGA microspheres…

Read the article
Articles — page 2 | Brilliant Blue Biosciences